Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 – 8. (Canceled)

9. (New) A compound of formula (I):



(I)

wherein:
R^1 represents a group selected from:











each ring of which optionally contains a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;

R^2 represents hydrogen, $-C_{1-6}$alkyl, $-C_{1-3}$alkylCONR^{a}R^b, $-C_{1-3}$alkylCO$_2$C$_{1-4}$alkyl, $-C_{2-3}$alkylmorpholino, $-CO_2C_{1-4}$alkyl, or $-C_{1-3}$alkylCO$_2$H;

R^a and R^b independently represent hydrogen, $-C_{1-6}$alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by $-C_{1-4}$alkyl, and optionally the S heteroatom is substituted by $(O)_n$;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}$alkyl, $-C_{2-4}$alkenyl, -CN, $-CF_3$, $-NR^aR^b$, $-C_{0-4}$alkylOR^e, $-C(O)R^f$ and $-C(O)NR^aR^b$;

R^e represents hydrogen or $-C_{1-6}$alkyl;
R^f represents $-C_{1-6}$alkyl;
Y is absent or represents $-C_{1-3}$ alkylene-;

R^3 represents hydrogen or $-C_{1-6}$alkyl;

R^4 represents $-C_{3-4}$alkenyl, $-CH_2CH_2OH$, $-CH_2CO_2H$, $-CH_2CH_2OC_{1-3}$alkyl, $-CH_2CH_2SO_2C_{1-3}$alkyl, -$CH_2CH_2NR^cR^d$, $-CH_2CONR^cR^d$, phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group containing at least one heteroatom selected from O, N or S and optionally substituted by $-C_{1-4}$alkyl;

R^c and R^d independently represent hydrogen, $-C_{1-6}$alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by $-C_{1-4}$alkyl;

or a pharmaceutically acceptable salt thereof.

10. (New) A compound according to claim 9, wherein R^1 represents a group selected from:









each ring of which optionally contains a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;
or a pharmaceutically acceptable salt thereof.

11. (New) A compound according to claim 9 wherein R^2 represents hydrogen, or a pharmaceutically acceptable salt thereof.

12. (New) A compound according to claim 9, wherein X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N

or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C_{1-4}alkyl or -NR^aR^b, or a pharmaceutically acceptable salt thereof.

13. (New) A compound according to claim 9, wherein Y is absent or represents C_{1-2} alkylene, or a pharmaceutically acceptable salt thereof.

14. (New) A compound according to claim 9, wherein R^3 represents hydrogen or methyl, or a pharmaceutically acceptable salt thereof.

15. (New) A compound according claim 9, wherein R^4 represents -C_{3-4}alkenyl, –CH_2CH_2OH, -CH_2CO_2H, -$CH_2CH_2OCH_3$, -$CH_2CH_2SO_2CH_3$, -$CH_2CH_2NR^cR^d$, -$CH_2CONR^cR^d$, phenyl or a 5- or 6- membered aromatic heterocyclic group containing one or two heteroatoms selected from O, N or S and optionally substituted by -C_{1-4}alkyl, or a pharmaceutically acceptable salt thereof.

16. (New) A compound according to claim 9, selected from:
4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(methylamino)ethyl]benzamide;
4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-(2-hydroxyethyl)-*N*-methylbenzamide;
4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-(2-pyridinylmethyl)benzamide;
4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(methylsulfonyl)ethyl]benzamide;
4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(methyloxy)ethyl]benzamide;
4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(3-pyridinyl)ethyl]benzamide;
4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-(2-phenylethyl)benzamide;
4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-(4-pyridinylmethyl)benzamide;
4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-(3-pyridinylmethyl)benzamide;
4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-(2-hydroxyethyl)-*N*-methylbenzamide;
4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-(phenylmethyl)benzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(methyloxy)ethyl]benzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-*N*-[2-(dimethylamino)ethyl]-3-fluoro-*N*-methylbenzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(methylsulfonyl)ethyl]benzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-2-propen-1-ylbenzamide;

N-(2-Amino-2-oxoethyl)-4-[3-({[(*E*)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methylbenzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-(4-pyridinylmethyl)benzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(1-pyrrolidinyl)ethyl]benzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-*N*-methylbenzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-(3-hydroxypropyl)-*N*-methylbenzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[3-(methylamino)-3-oxopropyl]benzamide;

4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(4-methyl-1*H*-imidazol-5-yl)ethyl]benzamide;

N-({4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluorophenyl}carbonyl)-*N*-methylglycine;

N-({4-[3-({[(*E*)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluorophenyl}carbonyl)glycine;

4-(3-{[(6-Chloro-1-benzothien-2-yl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-*N*-[2-(dimethylamino)ethyl]-3-fluoro-*N*-methylbenzamide;

4-(3-{[(6-Chloro-1-benzothien-2-yl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*-methyl-*N*-[2-(methylamino)ethyl]benzamide;

4-(3-{[(6-Chloro-1-benzothien-2-yl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*-methyl-*N*-[2-(3-pyridinyl)ethyl]benzamide;

N-(2-Aminoethyl)-4-(3-{[(6-chloro-1-benzothien-2-yl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*-methylbenzamide;

4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-*N*-[2-(dimethylamino)ethyl]-3-fluoro-*N*-methylbenzamide;

4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-methyl-*N*-[2-(3-pyridinyl)ethyl]benzamide;

4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-*N*-methylbenzamide; and
4-(3-{[(6-Chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*-methyl-*N*-[2-(methylamino)ethyl]benzamide;
or a pharmaceutically acceptable salt thereof.

17. (Withdrawn) A pharmaceutical composition comprising a compound according to claim 9 together with a pharmaceutical carrier and/or excipient.

18. (Withdrawn) A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of a compound according to claim 9.

19. (Withdrawn) A process for preparing a compound of formula (I) which comprises:
(a) reacting compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



(II)



(III)

OR:
(b) by reacting compounds of formula (XIII) with compounds of formula (VI):



(XIII)

R^3 $NHYR^4$ (VI)

(c) by reacting a compound of formula (I) where R^2 is hydrogen with a compound of formula (XVII):

$$R^2—T \quad \text{(XVII)}$$

where R^2 is -C_{1-6}alkyl, -C_{1-3}alkylCONR^{a}R^b, -C_{1-3}alkylCO$_2$C$_{1-4}$alkyl, -C_{2-3}alkylmorpholino or -CO$_2$C$_{1-4}$alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.